Maze Therapeutics, Inc. (MAZE)

Maze Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	149.61	29.16	99.92
Cash & Cash Equivalents	149.61	29.16	99.92
Cash Growth	-	-70.82%	-
Other Current Assets	4.35	4.95	6.23
Total Current Assets	153.96	34.11	106.15
Property, Plant & Equipment	-	8.85	12.4
Goodwill and Intangibles	-	26.14	28.83
Other Long-Term Assets	-	2.41	2.58
Total Long-Term Assets	-	37.39	43.81
Total Assets	-	71.5	149.96
Accounts Payable	-	2.02	1.59
Current Debt	-	4.49	4.32
Other Current Liabilities	17.56	9.81	14.87
Total Current Liabilities	17.56	16.32	20.78
Long-Term Debt	-	45.13	27.73
Total Long-Term Liabilities	-	45.13	27.73
Total Liabilities	-	61.45	48.51
Total Debt	79.16	49.62	32.06
Debt Growth	-	54.81%	-
Retained Earnings	-	-395.69	-295.27
Shareholders' Equity	-284.53	-373.85	-282.46
Net Cash / Debt	70.45	-20.47	67.86
Working Capital	136.4	17.79	85.37

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).